expresspharmaDecember 21, 2020
Tag: lupin , FDA , LDL-C , Colesevelam Hydrochloride Tablets , Welchol
Lupin has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Welchol Tablets, 625 mg, of Daiichi Sankyo. Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to:
reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).
Colesevelam Hydrochloride Tablets (RLD: Welchol) had an annual sales of approximately $159 million in the US (IQVIA MAT September 2020).
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: